Pulse Biosciences (Nasdaq:PLSE) today announced new positive clinical findings for its nPulse cardiac catheter system. nPulse uses proprietary nanosecond pulsed field ablation (nsPFA) energy to deliver a complete circumferential lesion in a single, brief energy application without the need to stack lesions. It also eliminates the need to stop, … [Read more...] about Pulse Biosciences has positive PFA data at HRS 2026
Pulse Biosciences
Pulse Biosciences names Liane Teplitsky as new COO
Pulse Biosciences (Nasdaq:PLSE) announced today that it appointed Liane Teplitsky as its new COO to further bolster its leadership team. Hayward, California-based Pulse Biosciences also expanded the role of Dr. David Kenigsberg to full-time chief medical officer (CMO). The pulsed field ablation (PFA) technology developer says the appointments … [Read more...] about Pulse Biosciences names Liane Teplitsky as new COO
Pulse Biosciences enrolls first patient in IDE study for PFA tech
Pulse Biosciences (Nasdaq:PLSE) announced today that it enrolled the first patients in its NANOPULSE-AF study. NANOPULSE-AF, an FDA investigational device exemption (IDE) study, evaluates the nPulse cardiac catheter system in the treatment of recurrent, drug-resistant, symptomatic paroxysmal AFib. Hayward, California-based Pulse Biosciences … [Read more...] about Pulse Biosciences enrolls first patient in IDE study for PFA tech
Pulse Biosciences shifts focus to accelerate cardiac pulsed field ablation program
Pulse Biosciences (Nasdaq:PLSE) announced a new strategic alignment to focus on its nPulse cardiac catheter ablation system. Hayward, California-based Pulse said it wants to prioritize and accelerate the development and future commercialization of nPulse. As a result, the company plans to centralize resources on the cardiac catheter platform, … [Read more...] about Pulse Biosciences shifts focus to accelerate cardiac pulsed field ablation program
Pulse Biosciences has positive data for thyroid nodule ablation
Pulse Biosciences (Nasdaq:PLSE) today announced clinical findings demonstrating the durability of its nPulse Vybrance system. Long-term follow-up data came from the nPulse Vybrance percutaneous electrode system first-in-human ablation study. It evaluated the ablation of benign thyroid nodules using nanosecond pulsed field ablation (nsPFA) … [Read more...] about Pulse Biosciences has positive data for thyroid nodule ablation
Pulse Biosciences wins FDA IDE to study PFA tech
Pulse Biosciences (Nasdaq:PLSE) announced today that the FDA granted an investigational device exemption (IDE) for a pulsed field ablation (PFA) study. The IDE enables the Hayward, California–based company to initiate the NANOPULSE-AF study of its nPulse cardiac catheter ablation system. The study evaluates the company's PFA technology in the … [Read more...] about Pulse Biosciences wins FDA IDE to study PFA tech
Pulse Biosciences to evaluate PFA in treating thyroid cancer
Pulse Biosciences (Nasdaq:PLSE) today announced a collaboration aimed at using its pulsed field ablation (PFA) technology for thyroid cancer treatment. The Hayward, California-based company entered into a research collaboration with the University of Texas MD Anderson Cancer Center. They aim to examine the use of the nPulse Vybrance percutaneous … [Read more...] about Pulse Biosciences to evaluate PFA in treating thyroid cancer
Pulse Biosciences enrolls first patient in NANOCLAMP PFA trial
Pulse Biosciences (Nasdaq:PLSE) today announced the enrollment of the first patient in its NANOCLAMP AF study for treating AFib. In September, the FDA granted investigational device exemption (IDE) for Pulse's nanosecond pulsed field ablation (nsPFA) system. Approval gave Pulse the green light to proceed with the initiation of the NANOCLAMP AF … [Read more...] about Pulse Biosciences enrolls first patient in NANOCLAMP PFA trial
Pulse Biosciences shares strong first-in-human PFA data
Pulse Biosciences (Nasdaq:PLSE) today announced clinical study results from a first-in-human study of its nPulse system. The company shared findings from the first-in-human feasibility study of the cardiac surgical system at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting in Copenhagen, Denmark. Pulse Biosciences' … [Read more...] about Pulse Biosciences shares strong first-in-human PFA data
Pulse Biosciences wins FDA IDE to conduct study of PFA tech for AFib
Pulse Biosciences (Nasdaq:PLSE) announced today that the FDA granted investigational device exemption (IDE) for its pulsed field ablation (PFA) system. The approval allows Pulse to proceed with the initiation of the NANOCLAMP AF study. NANOCLAMP AF evaluates the company's nanosecond PFA (nsPFA) Cardiac Surgery System for treating AFib. According … [Read more...] about Pulse Biosciences wins FDA IDE to conduct study of PFA tech for AFib
